1 in 4 Patients With NSCLC Respond Poorly to COVID-19 Vaccine

About 1 in 4 patients with non–small cell lung cancer have an unsatisfactory antibody response to the Omicron variant following COVID-19 vaccination, reports a new study.
MDedge News

source https://www.medscape.com/viewarticle/978694?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost